NTRK1 and cancer: This may help to explain the remarkable durable therapeutic response to Entrectinib reported in an infant with refractory metastatic TrkAIII-expressing NB [99] and also the durable responses to other Trk inhibitors reported in cancers driven by TrkA fusion oncogenes [13].